title: Residual leukemic cell counts in the bone marrow at the end point of intensive induction therapy may be a prognostic factor for acute myeloblastic leukemia in adults.
abstract: Between January 1990 and May 1994, 59 previously untreated adult patients with acute myeloblastic leukemia (AML) were treated with a combination of behenoyl-cytosine-arabinoside (BHAC), daunorubicin (DNR), 6-mercaptopurine (6-MP) and prednisolone (PSL). Forty one patients (69.5%) achieved complete remission (CR). The Kaplan-Meier analysis revealed an actuarial probability for remaining in remission of 36% in patients who achieved remission and a survival of 29% in all patients at 5 years. A favorable factor relative to achieving CR was performance status (P=0.04). In addition the presence of 300 cells/microl or less of residual leukemic cell counts in the bone marrow at the end point of induction therapy tended to favor remission (P=0.06) using the multivariate analysis with a multiple logistic regression model. In addition the residual leukemic cells counts of less than 300/microl in the bone marrow at the end point of induction therapy was the most significant factor for durable remission (P=0.05) by the Cox's proportional hazard model. We concluded that residual leukemic cells counts in the bone marrow at the end point of intensive induction therapy is a valuable prognostic factor for adults receiving response-oriented individualized induction therapy for AML.
authors.affiliation: First Department of Internal Medicine, Urafune Hospital, Yokohama City University School of Medicine, Kanagawa, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Fujisawa
authors.forename: A
authors.initials: A
authors.lastname: Maruta
authors.forename: S
authors.initials: S
authors.lastname: Motomura
authors.forename: H
authors.initials: H
authors.lastname: Fukawa
authors.forename: H
authors.initials: H
authors.lastname: Kanamori
authors.forename: K
authors.initials: K
authors.lastname: Ogawa
authors.forename: M
authors.initials: M
authors.lastname: Matsuzaki
authors.forename: H
authors.initials: H
authors.lastname: Miyashita
authors.forename: H
authors.initials: H
authors.lastname: Harano
authors.forename: T
authors.initials: T
authors.lastname: Murata
authors.forename: R
authors.initials: R
authors.lastname: Sakai
authors.forename: H
authors.initials: H
authors.lastname: Mohri
authors.forename: F
authors.initials: F
authors.lastname: Kodama
authors.forename: T
authors.initials: T
authors.lastname: Okubo
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001853:Bone Marrow / Q000473:pathology*; D002452:Cell Count; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D018365:Neoplasm, Residual / Q000473:pathology*; D011379:Prognosis; D016016:Proportional Hazards Models; D012074:Remission Induction / Q000379:methods*